News | Digital Pathology | September 22, 2023

Lunit SCOPE IO transforms pathologist discordance into concordance and predicts treatment response for breast cancer, enhancing the landscape of personal oncology care

Lunit SCOPE IO transforms pathologist discordance into concordance and predicts treatment response for breast cancer, enhancing the landscape of personal oncology care

Lunit AI-powered TIL analyzer, Lunit SCOPE IO 


September 22, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a pioneering study result, recently published in npj Breast Cancer (Nature Partner Journal Breast Cancer). The study presents significant advancements in breast cancer treatment planning utilizing Lunit's AI-powered tumor-infiltrating lymphocytes (TIL) analyzer, Lunit SCOPE IO. 

Breast cancer treatment outcomes are heavily influenced by the evaluation of TIL within the tumor microenvironment. However, the challenge of variability in the unaided TIL assessment has hindered TIL's use as a biomarker. Lunit has tackled this challenge with Lunit SCOPE IO, by enabling TIL assessment and immune phenotyping pan-cancer for effective diagnosis and treatment planning. 

In this study, in a comprehensive evaluation of 402 whole slide images of breast cancer, three pathologists initially assessed stromal TIL (sTIL) scores. Among 402 images, 210 cases (52.2%) showed sTIL score differences of less than 10 percentage points between pathologists. The standalone performance of Lunit SCOPE IO was notable, demonstrating a concordance correlation coefficient of 0.755 compared to the pathologists' scores. 

For the 226 slides (56.2%) that exhibited a 10-percentage point or greater variance between pathologists and the deep learning-based TIL analyzer, revised assessments were made with the assistance of Lunit SCOPE IO. This process reduced the number of discordant cases to just 116 (28.9%), with a statistically significant difference. The Lunit SCOPE IO-assisted revision also significantly improved the concordance correlation coefficient of the sTIL score among every two pathologists. 

The study's implications extend to treatment decisions for breast cancer patients. In cases where triple-negative and HER2-positive breast cancer patients underwent neoadjuvant chemotherapy, the Lunit SCOPE IO-assisted revised assessment revealed significantly higher sTIL scores in responders. Additionally, the AI-assisted revised assessment unveiled a correlation between sTIL-high tumors and positive chemotherapeutic responses. 

This groundbreaking research highlights the potential of AI analysis as a reliable reference for sTIL scoring in breast cancer assessment. By enhancing inter-pathologist concordance in sTIL interpretation and predicting neoadjuvant chemotherapy response, Lunit SCOPE IO offers a path towards improved breast cancer treatment pathways. 

“Breast cancer treatment decisions have been challenged by the inconsistent assessment of tumor-infiltrating lymphocytes. Lunit SCOPE IO addresses this issue by not only providing consistent and accurate assessments of TIL, but also predicting treatment outcomes," said Brandon Suh, CEO of Lunit. “This thoughtful use of Lunit AI has the potential to improve how we analyze and treat breast cancer. By paving the way for more effective and personalized treatment strategies, we are bringing a new era to patients and adding a powerful tool for oncologists.” 

For more information: www.lunit.com 

 

Related Breast Density Content:   

VIDEO: FDA Update on the US National Density Reporting Standard - A Discussion on the Final Rule    

One on One … with Wendie Berg, MD, PhD, FACR, FSBI    

Task Force Issues New Draft Recommendation Statement on Screening for Breast Cancer    

Creating Patient Equity: A Breast Density Legislative Update    

FDA Needs to Ensure that Information on Dense Breast Notifications are Clear and Understandable to all Members of the Public    

AI Provides Accurate Breast Density Classification    

VIDEO: The Impact of Breast Density Technology and Legislation    

VIDEO: Personalized Breast Screening and Breast Density    

VIDEO: Breast Cancer Awareness - Highlights of the NCoBC 2016 Conference    

Fake News: Having Dense Breast Tissue is No Big Deal    

The Manic World of Social Media and Breast Cancer: Gratitude and Grief    

  

Related Breast Imaging Content:    

Saving Lives Through Improved Screening Awareness 

Breast Cancer Risk Calculator Can Assess Risk of Advanced Breast Cancer   

Uncertainty About Breast Cancer Risk and Screening Choices and Perceived Risk Heighten with Breast Density Awareness Following Mammography   

Creating Patient Equity: A Breast Density Legislative Update   

FDA Needs to Ensure that Information on Dense Breast Notifications are Clear and Understandable to all Members of the Public   

AI Provides Accurate Breast Density Classification   

VIDEO: The Impact of Breast Density Technology and Legislation   

VIDEO: Personalized Breast Screening and Breast Density   

VIDEO: Breast Cancer Awareness - Highlights of the NCoBC 2016 Conference   

Fake News: Having Dense Breast Tissue is No Big Deal   

The Manic World of Social Media and Breast Cancer: Gratitude and Grief  


Related Content

Sponsored Content | Case Study | Enterprise Imaging

Having the most efficient clinical workflows with enhanced diagnostic capabilities is a major goal for clinicians and ...

Time May 16, 2024
arrow
News | FDA

May 14, 2024 — Indica Labs, the leading provider of digital pathology solutions, announced today that it received FDA ...

Time May 14, 2024
arrow
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Radiology Business

May 6, 2024 — ScreenPoint Medical’s Board of Directors has announced the appointment of Peter Kroese as the new Chief ...

Time May 06, 2024
arrow
News | Mammography

May 6, 2024 — Enable Me, a VELA Medical company, cited major new research by Siemens Healthineers entitled, “The future ...

Time May 06, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Feature | Breast Density | By Robert L. Bard, MD

Decades since the advent of breast scanning technology, innovations in noninvasive diagnostic imaging provide new ...

Time May 03, 2024
arrow
News | Radiology Business

May 2, 2024 — GE HealthCare has announced a new radiation therapy computed tomography (CT) solution with innovative ...

Time May 02, 2024
arrow
Feature | Radiology Business

Beginning this spring, ITN will begin sending out a bi-monthly survey to our readers on a variety of topics, which we ...

Time May 02, 2024
arrow
News | Breast Imaging

May 1, 2024 — Hologic, Inc., a global leader in women’s health, today announced that it signed a definitive agreement to ...

Time May 01, 2024
arrow
Subscribe Now